Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TNF | P01375 | 3/20 | 0.37 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.36 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.36 |
| ▸ | CTSK | P43235 | 3/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
| ▸ | PLK1 | P53350 | 2/20 | 0.35 |
| ▸ | PPARA | Q07869 | 2/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25320458 | 1.00 | PTPN1 (0.38) | PTPN1ALDH1A1TSHRTNFITGA4 | |
| SCHEMBL25899466 | 0.93 | TNF (0.39) | TNFPSMB1PSMB5AAK1PLK1 | |
| SCHEMBL25318213 | 0.85 | AAK1 (0.36) | TNFPSMB1PSMB5AAK1 | |
| SCHEMBL25318208 | 0.85 | AAK1 (0.36) | TNFPSMB1PSMB5AAK1 | |
| SCHEMBL25322149 | 0.84 | AAK1 (0.38) | TNFPSMB1PSMB5AAK1 | |
| SCHEMBL25322154 | 0.84 | AAK1 (0.38) | TNFPSMB1PSMB5AAK1 | |
| SCHEMBL25320533 | 0.84 | TIPARP (0.40) | TNFPSMB1PSMB5AAK1 | |
| SCHEMBL25320536 | 0.84 | TIPARP (0.40) | TNFPSMB1PSMB5AAK1 | |
| SCHEMBL25321393 | 0.82 | TIPARP (0.46) | PTPN1ITGA4ITGB7P2RX3PLK1 | |
| SCHEMBL25321386 | 0.82 | TIPARP (0.46) | PTPN1ITGA4ITGB7P2RX3PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023147418-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365529-A1 | PARP7 INHIBITORS | PARP1, PARP11, PARP2 | PTPN1 4396/4885ALDH1A1 1171/4885TSHR 4640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.